1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Alpha Glucosidase Inhibitors -Pipeline Insights, 2016

Alpha Glucosidase Inhibitors -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “Alpha Glucosidase Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Alpha Glucosidase Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Alpha Glucosidase Inhibitors. DelveInsight’s Report also assesses the Alpha Glucosidase Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Alpha Glucosidase Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Alpha Glucosidase Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Alpha Glucosidase Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Alpha Glucosidase Inhibitors -Pipeline Insights, 2016

- Alpha Glucosidase Inhibitors Overview
- Alpha Glucosidase Inhibitors Disease Associated
- Alpha Glucosidase Inhibitors Pipeline Therapeutics
- Alpha Glucosidase Inhibitors Therapeutics under Development by Companies
- Alpha Glucosidase Inhibitors Filed and Phase III Products
- Comparative Analysis
- Alpha Glucosidase Inhibitors Phase II Products
- Comparative Analysis
- Alpha Glucosidase Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Alpha Glucosidase Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Alpha Glucosidase Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Alpha Glucosidase Inhibitors - Discontinued Products
- Alpha Glucosidase Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for Alpha Glucosidase Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Alpha Glucosidase Inhibitors by Therapy Area, 2016
- Number of Products under Development for Alpha Glucosidase Inhibitors, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Alpha Glucosidase Inhibitors Assessment by Monotherapy Products
- Alpha Glucosidase Inhibitors Assessment by Combination Products
- Alpha Glucosidase Inhibitors Assessment by Route of Administration
- Alpha Glucosidase Inhibitors Assessment by Stage and Route of Administration
- Alpha Glucosidase Inhibitors Assessment by Molecule Type
- Alpha Glucosidase Inhibitors Assessment by Stage and Molecule Type
- Alpha Glucosidase Inhibitors Therapeutics - Discontinued Products
- Alpha Glucosidase Inhibitors Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Alpha Glucosidase Inhibitors by Therapy Area, 2016
- Number of Products under Development for Alpha Glucosidase Inhibitors, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Alpha Glucosidase Inhibitors Assessment by Monotherapy Products
- Alpha Glucosidase Inhibitors Assessment by Combination Products
- Alpha Glucosidase Inhibitors Assessment by Route of Administration
- Alpha Glucosidase Inhibitors Assessment by Stage and Route of Administration
- Alpha Glucosidase Inhibitors Assessment by Molecule Type
- Alpha Glucosidase Inhibitors Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Global and Chinese Acarbose Industry Market Research Report

2016 Global and Chinese Acarbose Industry Market Research Report

  • $ 2800
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Acarbose Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Acarbose industry with a focus on the Chinese market. ...

Analyzing the Global Diabetes Market 2016

Analyzing the Global Diabetes Market 2016

  • $ 1000
  • Industry report
  • September 2016
  • by Aruvian's R'search

Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. Oral anti-diabetics ...

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

  • $ 2349
  • Industry report
  • August 2016
  • by Roots Analysis Private Ltd.

INTRODUCTION Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive ...


Download Unlimited Documents from Trusted Public Sources

Type 2 Diabetes Statistics in the US

  • November 2016
    19 pages
  • Diabetes  

    Type 2 Diabetes  

  • United States  

View report >

Therapy Market in the UK

  • October 2016
    120 pages
  • Anti-Infective  

    Lipid Modifying...  

    Therapy  

  • United Kingdom  

View report >

Sodium-Glucose Co-Transporter 2 Inhibitor Market and Heart Failure Statistics in the US

  • September 2016
    21 pages
  • Sodium-Glucose ...  

    Antidiabetics  

    Cardiovascular ...  

  • United States  

View report >

Insulin Market

11 months ago

Related Market Segments :

Alpha-Glucosidase Inhibitor

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.